817 related articles for article (PubMed ID: 19479202)
41. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
42. Taming cancer by inducing immunity via dendritic cells.
Palucka AK; Ueno H; Fay JW; Banchereau J
Immunol Rev; 2007 Dec; 220():129-50. PubMed ID: 17979844
[TBL] [Abstract][Full Text] [Related]
43. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.
Russo V; Cipponi A; Raccosta L; Rainelli C; Fontana R; Maggioni D; Lunghi F; Mukenge S; Ciceri F; Bregni M; Bordignon C; Traversari C
J Clin Invest; 2007 Oct; 117(10):3087-96. PubMed ID: 17885685
[TBL] [Abstract][Full Text] [Related]
44. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
45. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
Lynch DH
Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
[TBL] [Abstract][Full Text] [Related]
46. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
Dullaers M; Thielemans K
J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
[TBL] [Abstract][Full Text] [Related]
47. Coupled for cross-presentation in tumor immunotherapy.
Pang B; Neefjes J
Sci Transl Med; 2010 Aug; 2(44):44ps40. PubMed ID: 20702855
[TBL] [Abstract][Full Text] [Related]
48. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].
Punt CJ; de Vries IJ; Mulders PF; Adema GJ; Figdor CG
Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2408-14. PubMed ID: 10608974
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy of cancer using dendritic cells.
Morse MA; Lyerly HK
Cytokines Cell Mol Ther; 1998 Mar; 4(1):35-44. PubMed ID: 9557215
[TBL] [Abstract][Full Text] [Related]
50. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.
Van Nuffel AM; Corthals J; Neyns B; Heirman C; Thielemans K; Bonehill A
Methods Mol Biol; 2010; 629():405-52. PubMed ID: 20387165
[TBL] [Abstract][Full Text] [Related]
51. Migration of dendritic cell based cancer vaccines: in vivo veritas?
Adema GJ; de Vries IJ; Punt CJ; Figdor CG
Curr Opin Immunol; 2005 Apr; 17(2):170-4. PubMed ID: 15766677
[TBL] [Abstract][Full Text] [Related]
52. Gene transfer approaches in cancer immunotherapy.
Larin SS; Georgiev GP; Kiselev SL
Gene Ther; 2004 Oct; 11 Suppl 1():S18-25. PubMed ID: 15454953
[TBL] [Abstract][Full Text] [Related]
53. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
54. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.
Tacken PJ; Figdor CG
Semin Immunol; 2011 Feb; 23(1):12-20. PubMed ID: 21269839
[TBL] [Abstract][Full Text] [Related]
55. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.
Breckpot K; Heirman C; Neyns B; Thielemans K
J Gene Med; 2004 Nov; 6(11):1175-88. PubMed ID: 15468193
[TBL] [Abstract][Full Text] [Related]
56. Exploiting dendritic cells for active immunotherapy of cancer and chronic infection.
O'Neill D; Bhardwaj N
Methods Mol Med; 2005; 109():1-18. PubMed ID: 15585909
[TBL] [Abstract][Full Text] [Related]
57. Reengineering dendritic cell-based anti-cancer vaccines.
Koski GK; Cohen PA; Roses RE; Xu S; Czerniecki BJ
Immunol Rev; 2008 Apr; 222():256-76. PubMed ID: 18364007
[TBL] [Abstract][Full Text] [Related]
58. RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.
Tyagi RK; Mangal S; Garg N; Sharma PK
Expert Rev Anticancer Ther; 2009 Jan; 9(1):97-114. PubMed ID: 19105710
[TBL] [Abstract][Full Text] [Related]
59. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines?
Sioud M
Scand J Immunol; 2009 Dec; 70(6):516-25. PubMed ID: 19906192
[TBL] [Abstract][Full Text] [Related]
60. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
